For Untreated HIV, a Two-Drug Regimen Matched Three Drugs on Immune Recovery

For decades, standard HIV treatment has meant a three-drug cocktail. Growing evidence — including new data presented this week — suggests that for many people starting treatment, two drugs work just as well.

Why three drugs became standard

The convention was a response to resistance rather than a requirement of the biology.

HIV replicates at enormous rates and copies its genome inaccurately, so mutations arise constantly. Treatment with a single drug fails predictably: a virus resistant to that drug already exists somewhere in the population and expands once everything else is suppressed.

Combining drugs with different mechanisms made resistance improbable, because a virus would need multiple simultaneous mutations to escape all of them at once. Three was the number that reliably achieved durable suppression with the drugs available at the time.

The early agents were also weaker individually and had lower barriers to resistance, so the redundancy was doing real work.

What the new analysis found

Researchers compared treatment-naive adults starting dolutegravir plus lamivudine against those on a standard three-drug, integrase-inhibitor-based regimen.

Over three years, the two approaches showed no significant difference in immune recovery, measured by the CD4-to-CD8 ratio.

Why that ratio was the measure

The choice of endpoint is more informative than viral suppression would have been, and the reason is that suppression was already established.

CD4 cells are the immune cells HIV destroys, and CD8 cells expand in response to chronic infection. The ratio between them captures how disordered the immune system remains, and it does not fully normalise in everyone even when virus is undetectable.

A low ratio despite successful treatment is associated with persistent inflammation and with cardiovascular disease, certain cancers and other non-AIDS conditions that now account for much of the illness in treated HIV.

So the question the analysis addressed was not whether two drugs control the virus — that was known — but whether they allow equivalent immune reconstitution over years, which is the measure that bears on long-term health.

Building on prior evidence

The finding reinforces the randomised GEMINI studies, where the two-drug combination matched three drugs on viral suppression — about 92% of the two-drug group versus 89% of the three-drug group reached undetectable virus at 48 weeks, with no treatment-emergent resistance.

The absence of emergent resistance is the critical detail. The theoretical objection to removing a drug is that it lowers the genetic barrier and permits escape, and that is the outcome that did not occur.

Dolutegravir’s own high barrier to resistance is why. The virus struggles to develop resistance to it without simultaneously becoming less able to replicate, which means one drug is carrying much of the protection the third drug previously provided.

Why fewer drugs is worth pursuing

Fewer drugs can mean fewer long-term side effects, lower cost and simpler regimens — while maintaining effectiveness.

The cumulative-exposure argument has grown more important as outcomes improved. Someone diagnosed at thirty may now take medication for fifty years, and the drug removed from the regimen — commonly a nucleotide analogue — has been associated with effects on kidney function and bone density accumulating over decades.

Cost matters at population scale, particularly where treatment programmes are publicly funded and expanding.

Who it is not for

Two-drug therapy is not right for everyone; certain patients still need three.

The exclusions follow from the mechanism. Very high viral loads at baseline, hepatitis B co-infection requiring agents active against both viruses, existing resistance, and situations where treatment must begin before resistance testing returns all argue for the additional drug.

How this fits the shift to long-acting therapy

Simplification is happening along two dimensions at once, and they interact.

Reducing the number of drugs is one. Reducing dosing frequency is the other: injectable regimens given every one or two months have been approved as alternatives to daily oral therapy, and longer intervals are in development.

Fewer drugs makes long-acting formulations more feasible. Each agent in an injectable regimen must be formulated to release slowly at therapeutic concentrations for weeks, and every additional drug adds a compound that must behave correctly over that period and be delivered in an injectable volume a patient will accept.

The clinical case for long-acting therapy rests on adherence. Daily medication over decades is difficult to sustain perfectly, and gaps risk resistance. It also removes the daily reminder of diagnosis and the risk of disclosure through visible pill bottles — considerations patients rate highly and clinical endpoints do not capture.

The trade-off is that a long-acting drug cannot be stopped if a problem emerges; it clears slowly, and sub-therapeutic concentrations during that tail are exactly the conditions in which resistance develops.

The choice remains individual, but the accumulating data continue to shift HIV care toward doing more with less. General information, not medical advice.